Investor Webinar
LONDON and PHILADELPHIA - May 12, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina Coughlin, Chief Executive Officer, and Michelle Morrow, Chief Scientific Officer, will be presenting at a webinar on 15 May 2025 at 6.00 pm (BST).
The webinar is open to all existing and potential investors and will focus on the Company's recent data presentations on its proprietary pre|CISION® candidates FAP-Dox (AVA6000) and FAP-EXd (AVA6103) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.
The Company welcomes investor interaction so there will be a Q&A session after the presentation and questions can be submitted pre-event as part of the registration process. The webinar will be hosted by Turner Pope Investments.
Investors can register for the event by using the following link:
https://www.turnerpope.com/register/
-Ends-
For further information from Avacta, please contact:
| Avacta Group plc Michael Vinegrad, Group Communications Director | |
|
|
|
| Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
|
|
| Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers
| |
| ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor Contact Renee Leck THRUST Strategic Communications
|
|
| Media Contact Carly Scaduto Carly Scaduto Consulting |
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® Platform
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.